Compare FTLF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 147.4M |
| IPO Year | 2006 | 1999 |
| Metric | FTLF | AGEN |
|---|---|---|
| Price | $10.04 | $3.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $21.50 | $14.50 |
| AVG Volume (30 Days) | 27.6K | ★ 800.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 0.17 | ★ 1.02 |
| Revenue | $21,744,000.00 | ★ $42,877,086.00 |
| Revenue This Year | $45.76 | $107.63 |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $60.76 | ★ $3.11 |
| Revenue Growth | 11.52 | ★ 89.95 |
| 52 Week Low | $8.67 | $2.71 |
| 52 Week High | $20.98 | $7.34 |
| Indicator | FTLF | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 37.45 |
| Support Level | $8.79 | $2.91 |
| Resistance Level | $15.34 | $3.26 |
| Average True Range (ATR) | 0.83 | 0.26 |
| MACD | 0.17 | -0.07 |
| Stochastic Oscillator | 45.88 | 5.99 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.